stockrowUFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
- Revenue
- +11.6%
- EPS
- +25.6%
- Free cash flow
- −35.8%
- Total debt
- −40.2%
Quarter to September 2026, against a year earlier
Follow UFPT
Alert me
UFP Technologies, Inc. (UFPT) EPS (diluted)
UFP Technologies, Inc.'s EPS (diluted) for fiscal 2025 was $8.75, up 15.4% from $7.58 in fiscal 2024. Over the twelve months to 30 September 2026 it was $9.81. Over the past ten years it has ranged from $1.05 (fiscal 2015) to $8.75 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 5 consecutive fiscal years. UFP Technologies, Inc. ranks 3rd of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $8.75 | 15.44% |
| FY2024 | $7.58 | 30.02% |
| FY2023 | $5.83 | 6.97% |
| FY2022 | $5.45 | 160.77% |
| FY2021 | $2.09 | 18.08% |
| FY2020 | $1.77 | (32.70%) |
| FY2019 | $2.63 | 36.27% |
| FY2018 | $1.93 | 53.17% |
| FY2017 | $1.26 | 14.55% |
| FY2016 | $1.10 | 4.76% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.64 | (1.45%) |
| Jun 2026 | $2.68 | 19.64% |
| Mar 2026 | $2.24 | (0.44%) |
| Dec 2025 | $2.25 | 6.64% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UFPT UFP Technologies, Inc. | $9.81 |
| TMDX TransMedics Group, Inc. compare | $3.69 |
| INSP Inspire Medical Systems, Inc. compare | $3.44 |
| BFLY Butterfly Network, Inc. compare | −$0.21 |
| NEOG Neogen Corporation compare | −$0.25 |
| AXGN AxoGen, Inc. compare | −$0.65 |
| NVCR NovoCure Limited compare | −$1.06 |
| ESTA Establishment Labs Holdings Inc. compare | −$1.31 |
| ALMR Alamar Biosciences, Inc. compare | −$2.77 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on UFPT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement